亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy

作者
Yuka Hayakawa,Nobuharu Tamaki,Hiroyuki Nakanishi,Masayuki Kurosaki,Yuki Tanaka,Kento Inada,Shun Ishido,Sakura Kirino,Koji Yamashita,Tsubasa Nobusawa,Hiroaki Matsumoto,Tatsuya Kakegawa,Mayu Higuchi,Kenta Takaura,Shohei Tanaka,Chiaki Maeyashiki,Shun Kaneko,Yutaka Yasui,Yuka Takahashi,Kaoru Tsuchiya
出处
期刊:Internal Medicine [The Japanese Society of Internal Medicine]
卷期号:62 (7): 973-978 被引量:5
标识
DOI:10.2169/internalmedicine.0212-22
摘要

Objective Rifaximin is used to treat hepatic encephalopathy. However, whether or not rifaximin and lactulose combination therapy can enhance the treatment outcomes and reduce the hospitalization rate of patients with hepatic encephalopathy that are resistant to lactulose has yet to be determined. The present study investigated the hospitalization rate before and after rifaximin add-on therapy in patients resistant to lactulose. Methods A total of 36 patients who were resistant to lactulose with add-on rifaximin therapy were enrolled. Patients who were hospitalized and/or did not achieve normalization of ammonia levels under lactulose administration were defined as treatment-resistant. The primary outcome was the change in hospitalization rate due to hepatic encephalopathy at 24 weeks before and after rifaximin administration. Results Before rifaximin administration, 15 (41.6%) patients were hospitalized due to hepatic encephalopathy. After rifaximin administration, 8 (22.2%) patients were hospitalized due to hepatic encephalopathy. The hospitalization rates were significantly reduced after rifaximin administration (p=0.02). The median (interquartile range) ammonia levels upon rifaximin administration (baseline) and 8, 12, and 24 weeks after rifaximin administration were 124 (24-310) μg/dL, 78 (15-192) μg/dL, 67 (21-233) μg/dL, and 77 (28-200) μg/dL, respectively. Furthermore, the ammonia levels were significantly reduced by rifaximin add-on therapy (p=0.005, p=0.01, and p=0.01). Conclusion The addition of rifaximin to lactulose treatment in treatment-resistant patients decreases the hospitalization rate among patients with hepatic encephalopathy and may be used as an add-on treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
李云昊完成签到 ,获得积分10
6秒前
343123完成签到,获得积分10
8秒前
huang完成签到,获得积分10
10秒前
11秒前
泥豪泥嚎完成签到,获得积分10
12秒前
14秒前
科研通AI6.4的应助被甘乐采纳,获得10
17秒前
17秒前
感动沛容发布了新的文献求助10
18秒前
彩色南烟完成签到,获得积分10
22秒前
顺利的谷菱完成签到,获得积分10
22秒前
的速度发布了新的文献求助10
23秒前
可久斯基完成签到 ,获得积分10
25秒前
斯文钢笔发布了新的文献求助10
25秒前
打打的应助被A2311采纳,获得10
29秒前
沉默岩完成签到,获得积分10
30秒前
32秒前
33秒前
萧雨墨发布了新的文献求助30
36秒前
柳贯一发布了新的文献求助10
36秒前
36秒前
A2311发布了新的文献求助10
37秒前
碳烤小肥羊完成签到 ,获得积分10
38秒前
易28完成签到,获得积分10
39秒前
huang发布了新的文献求助10
40秒前
43秒前
44秒前
余香的应助被无奈诗槐采纳,获得10
47秒前
paradox完成签到 ,获得积分10
49秒前
suyongye关注了科研通微信公众号
51秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
53秒前
53秒前
fairytaler的应助被科研通管家采纳,获得10
53秒前
Hayat的应助被科研通管家采纳,获得30
53秒前
Hayat的应助被科研通管家采纳,获得30
53秒前
星辰大海的应助被科研通管家采纳,获得10
53秒前
顾矜的应助被科研通管家采纳,获得10
53秒前
小马甲的应助被科研通管家采纳,获得10
54秒前
贺知什么书完成签到,获得积分10
54秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190060
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851884
捐赠科研通 7788155
什么是DOI,文献DOI怎么找? 3436233
关于科研通互助平台的介绍 2559935
邀请新用户注册赠送积分活动 2482792